176 related articles for article (PubMed ID: 26646277)
1. Value of Early Check-Up of Carbohydrate Antigen 19-9 Levels for Pancreatic Cancer Screening in Asymptomatic New-Onset Diabetic Patients.
Choe JW; Kim JS; Kim HJ; Hwang SY; Joo MK; Lee BJ; Kim JH; Yeon JE; Park JJ; Byun KS; Bak YT
Pancreas; 2016; 45(5):730-4. PubMed ID: 26646277
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of CA 19-9 for pancreatic cancer screening in patients with new-onset diabetes.
Choe JW; Kim HJ; Kim JS; Cha J; Joo MK; Lee BJ; Park JJ; Bak YT
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):263-268. PubMed ID: 29752133
[TBL] [Abstract][Full Text] [Related]
3. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes.
Guo Q; Kang M; Zhang B; Chen Y; Dong X; Wu Y
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1627-31. PubMed ID: 20174821
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.
Kim JE; Lee KT; Lee JK; Paik SW; Rhee JC; Choi KW
J Gastroenterol Hepatol; 2004 Feb; 19(2):182-6. PubMed ID: 14731128
[TBL] [Abstract][Full Text] [Related]
6. Two different types of diabetes mellitus in pancreatic cancer population. Comparative study between new onset and long standing diabetes mellitus on 76 patients with pancreatic cancer.
Tanţău A; Negrean V; Alexescu T; Para I; Tărmure S; Casoinic F; Sâmpelean D; Mocanu T; Tanţău M
Rom J Intern Med; 2014; 52(1):18-23. PubMed ID: 25000673
[TBL] [Abstract][Full Text] [Related]
7. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
8. Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer.
Franklin O; Jonsson P; Billing O; Lundberg E; Öhlund D; Nyström H; Lundin C; Antti H; Sund M
Ann Surg; 2018 Apr; 267(4):775-781. PubMed ID: 28425921
[TBL] [Abstract][Full Text] [Related]
9. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
11. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer.
Chari ST; Klee GG; Miller LJ; Raimondo M; DiMagno EP
Gastroenterology; 2001 Sep; 121(3):640-5. PubMed ID: 11522748
[TBL] [Abstract][Full Text] [Related]
12. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
13. [Is the carbohydrate antigen Ca 19.9 useful in the diagnosis of pancreatic carcinoma?].
Santander C; Jiménez I; Martín E; Melón A; Pajares JM
Rev Esp Enferm Dig; 1994 Nov; 86(5):819-21. PubMed ID: 7848693
[TBL] [Abstract][Full Text] [Related]
14. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
[TBL] [Abstract][Full Text] [Related]
16. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
[TBL] [Abstract][Full Text] [Related]
18. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study.
Zubarik R; Gordon SR; Lidofsky SD; Anderson SR; Pipas JM; Badger G; Ganguly E; Vecchio J
Gastrointest Endosc; 2011 Jul; 74(1):87-95. PubMed ID: 21704809
[TBL] [Abstract][Full Text] [Related]
19. CA 19-9: handle with care.
Galli C; Basso D; Plebani M
Clin Chem Lab Med; 2013 Jul; 51(7):1369-83. PubMed ID: 23370912
[TBL] [Abstract][Full Text] [Related]
20. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
